1. Show article details.

    BRIEF-Mozart Therapeutics Launches With $55 Mln Series A Financing

    Reuters – 8:17 AM ET 10/26/2021

    Eli Lilly and Co (LLY): * MOZART THERAPEUTICS LAUNCHES WITH $55 MILLION SERIES A FINANCING. * MOZART THERAPEUTICS - SERIES A FINANCING LED BY ARCH VENTURE PARTNERS ALONG WITH SOFINNOVA PARTNERS. * MOZART THERAPEUTICS - ADDITIONAL INVESTORS IN FUNDING ROUND INCLUDE ELI LILLY & COMPANY, MRL VENTURES FUND LEAPS BY BAYER, OTHERS Source text for Eikon: Further company coverage:

  2. Show article details.

    Lilly kicks off application for Alzheimer's drug U.S. approval

    Reuters – 6:50 AM ET 10/26/2021

    Eli Lilly (LLY) said on Tuesday it has started the application process for a U.S. approval of its closely watched experimental Alzheimer's drug and expects a regulatory decision by the second half of 2022, potentially setting it up against rival Biogen's recently approved Aduhelm.

  3. Show article details.

    BRIEF-Eli Lilly Reports Q3 Earnings Per Share Of $1.22

    Reuters – 6:32 AM ET 10/26/2021

    Eli Lilly and Co (LLY): * LILLY REPORTS ROBUST THIRD-QUARTER 2021 FINANCIAL RESULTS AS PIPELINE SUCCESS STRENGTHENS FUTURE GROWTH POTENTIAL. * Q3 EARNINGS PER SHARE $1.22. * Q3 REVENUE ROSE 18 PERCENT TO $6.773 BILLION. * Q3 NON-GAAP EARNINGS PER SHARE $1.94. * ELI LILLY (LLY) - QTRLY REVENUE ATTRIBUTABLE TO OUR NEWER MEDICINES GREW MORE THAN 35 PERCENT AND REPRESENTED NEARLY 60 PERCENT OF OUR CORE BUSINESS.

  4. Show article details.

    Lilly kicks off application for Alzheimer's drug U.S. approval

    Reuters – 6:31 AM ET 10/26/2021

    -Eli Lilly (LLY) said on Tuesday it has started the application process for a U.S. approval of its closely watched experimental Alzheimer's drug and expects a regulatory decision by the second half of 2022, potentially setting it up against rival Biogen's recently approved Aduhelm.

  5. Show article details.

    Lilly third quarter profit falls 8% on higher costs

    Reuters – 6:30 AM ET 10/26/2021

    Eli Lilly and Co (LLY) on Tuesday reported an 8% fall in third quarter profit, reflecting higher research and development costs. Net income fell to $1.11 billion or $1.22 per share, in the quarter ended Sept. 30, from $1.21 billion, or $1.33 per share a year earlier.

  6. Show article details.

    Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

    PR Newswire – 6:25 AM ET 10/26/2021

    INDIANAPOLIS, Oct. 26, 2021 Eli Lilly and Company (LLY) announced financial results for the third quarter of 2021 today. "Lilly demonstrated strong performance again this quarter. Certain financial information for 2021 and 2020 is presented on both a reported and a non-GAAP basis. Key Events Over the Last Three MonthsRegulatory. Clinical. Business Development/Other Developments.

  7. Show article details.

    Marketmind: Trillion-dollar Tesla

    Reuters – 3:31 AM ET 10/26/2021

    A look at the day ahead from Sujata Rao. Apple, Amazon (AMZN), Microsoft (MSFT), Alphabet... and Tesla. The news was less cheerful from Facebook (FB) which is contending with whistleblowers and falling popularity among the young. All in all, the global equity index is inching back towards the record highs hit early-September.

  8. Show article details.

    MORNING BID-Trillion-dollar Tesla

    Reuters – 3:02 AM ET 10/26/2021

    A look at the day ahead from Sujata Rao. Apple, Amazon (AMZN), Microsoft (MSFT), Alphabet... and Tesla. The news was less cheerful from Facebook (FB) which is contending with whistleblowers and falling popularity among the young. All in all, the global equity index is inching back towards the record highs hit early-September.

  9. Show article details.

    Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris

    Reuters – 7:09 AM ET 10/20/2021

    - Cigna Corp's (CI) pharmacy benefit unit said on Wednesday it will prefer Viatris Inc (VTRS) and Biocon Biologics Ltd's insulin drug Semglee, a cheaper alternative to Sanofi SA's Lantus, on the list of medicines it reimburses on behalf of health insurers. The unit, Express Scripts, said it expects cost savings of $20 million in 2022 by preferring the Semglee injection.

  10. Show article details.

    Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris

    Reuters – 7:00 AM ET 10/20/2021

    Cigna Corp's (CI) pharmacy benefit unit said on Wednesday it will prefer Viatris Inc (VTRS) and Biocon Biologics Ltd's insulin drug Semglee, a cheaper alternative to Sanofi SA's Lantus, on the list of medicines it reimburses on behalf of health insurers. The unit, Express Scripts, said it expects cost savings of $20 million in 2022 by preferring the Semglee injection.

  11. Show article details.

    Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk

    PR Newswire – 6:45 AM ET 10/19/2021

    INDIANAPOLIS, Oct. 19, 2021 Adults with type 2 diabetes with increased cardiovascular risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from Eli Lilly and Company's  SURPASS-4 clinical trial, which were published today in The Lancet.

  12. Show article details.

    Lilly Declares Fourth-Quarter 2021 Dividend

    PR Newswire – 2:52 PM ET 10/18/2021

    INDIANAPOLIS, Oct. 18, 2021  The board of directors of Eli Lilly and Company (LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on December 10, 2021 to shareholders of record at the close of business on November 15, 2021.

  13. Show article details.

    BRIEF-Lilly Announces Updated Verzenio Phase 3 Monarche Trial Data Presented At Esmo Virtual Plenary And Simultaneously Published In The Annals Of Oncology

    Reuters – 1:37 PM ET 10/14/2021

    Eli Lilly and Co (LLY): * LILLY ANNOUNCES UPDATED VERZENIO® PHASE 3 MONARCHE TRIAL DATA PRESENTED AT ESMO VIRTUAL PLENARY AND SIMULTANEOUSLY PUBLISHED IN THE ANNALS OF ONCOLOGY. * ELI LILLY (LLY) - CONSISTENT VERZENIO TREATMENT BENEFIT IN REDUCING RISK OF RECURRENCE OBSERVED IN PATIENTS REGARDLESS OF KI-67 SCORE.

  14. Show article details.

    Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology

    PR Newswire – 1:30 PM ET 10/14/2021

    INDIANAPOLIS, Oct. 14, 2021  Eli Lilly and Company (LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio® in combination with standard adjuvant endocrine therapy for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high risk early breast cancer.

  15. Show article details.

    BRIEF-Hemogenyx Pharma Signs Agreement With Eli Lilly

    Reuters – 10:34 AM ET 10/13/2021

    Hemogenyx Pharmaceuticals PLC (HOPHF): * HEMOGENYX PHARMA PLC - CDX LICENCE AGREEMENT. * Hemogenyx Pharmaceuticals PLC (HOPHF) - SIGNED A LICENCE AGREEMENT WITH GLOBAL BIOPHARMACEUTICAL COMPANY ELI LILLY AND COMPANY. * Hemogenyx Pharmaceuticals PLC (HOPHF) - UNDER AGREEMENT, COMPANY HAS AGREED TO MAKE AN UP-FRONT PAYMENT TO LILLY OF US$250,000 Source text for Eikon: Further company coverage:

  16. Show article details.

    BRIEF-FDA Approves Verzenio As The First And Only Cdk4/6 Inhibitor For Certain People With Breast Cancer

    Reuters – 6:51 AM ET 10/13/2021

    Eli Lilly and Co (LLY): * FDA APPROVES VERZENIO® AS THE FIRST AND ONLY CDK4/6 INHIBITOR FOR CERTAIN PEOPLE WITH HR+ HER2- HIGH RISK EARLY BREAST CANCER. * ELI LILLY (LLY) - VERZENIO LABELLING CONTAINS WARNINGS, PRECAUTIONS FOR DIARRHEA, NEUTROPENIA, INTERSTITIAL LUNG DISEASE, HEPATOTOXICITY.

  17. Show article details.

    FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer

    PR Newswire – 6:45 AM ET 10/13/2021

    INDIANAPOLIS, Oct. 13, 2021  The U.S. Food and Drug Administration has approved Eli Lilly and Company's Verzenio®, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA...

  18. Show article details.

    Hemogenyx Signs Licensing Agreement With Eli Lilly for Antibody

    DJ Business News – 4:54 AM ET 10/13/2021

    Hemogenyx Pharmaceuticals PLC (HOPHF) said Wednesday that it has signed an agreement with biopharmaceutical company Eli Lilly& Co., granting Hemogenyx an exclusive world-wide license to an antibody that can be used to treat blood cancers. The biopharmaceutical group said the license is for certain intellectual property developed by Lilly relating to a CDX bispecific antibody, including the treatment of acute myeloid leukemia. Under an earlier agreement between the companies,...

  19. Show article details.

    Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement

    PR Newswire – 10:00 AM ET 10/12/2021

    INDIANAPOLIS, Oct. 12, 2021  Eli Lilly (LLY) and Company will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time.

  20. Show article details.

    AstraZeneca antibody cocktail study shows success treating COVID-19

    Reuters – 11:16 AM ET 10/11/2021

    * Shortly after infection, drug cuts risk of deterioration. * Astra sees shot's main use in preventative setting. * Faces competition from other antibodies, Merck (MRK) tablet. By Ludwig Burger, Yadarisa Shabong and Sachin Ravikumar.

Page:

Today's and Upcoming Events

  • Nov
    12

    LLY ex-Dividend for $0.85 on 11/12/2021

    • Announce Date: 10/18/2021
    • Record Date: 11/15/2021
    • Pay Date: 12/10/2021

Past Events (last 90 days)

  • Oct
    26

    LLY announced Q3 earnings of $1.94 per share (vs. $1.98)

  • Aug
    12

    LLY ex-Dividend for $0.85 on 08/12/2021

    • Announce Date: 06/29/2021
    • Record Date: 08/13/2021
    • Pay Date: 09/10/2021
Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.